Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2015 6
2016 6
2017 12
2018 4
2019 5
2020 4
2021 3
2022 14
2023 13
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

64 results

Results by year

Filters applied: . Clear all
Page 1
Considerations for the Use of Phage Therapy in Clinical Practice.
Suh GA, Lodise TP, Tamma PD, Knisely JM, Alexander J, Aslam S, Barton KD, Bizzell E, Totten KMC, Campbell JL, Chan BK, Cunningham SA, Goodman KE, Greenwood-Quaintance KE, Harris AD, Hesse S, Maresso A, Nussenblatt V, Pride D, Rybak MJ, Sund Z, van Duin D, Van Tyne D, Patel R; Antibacterial Resistance Leadership Group. Suh GA, et al. Antimicrob Agents Chemother. 2022 Mar 15;66(3):e0207121. doi: 10.1128/AAC.02071-21. Epub 2022 Jan 18. Antimicrob Agents Chemother. 2022. PMID: 35041506 Free PMC article. Review.
Priorities and Progress in Gram-negative Bacterial Infection Research by the Antibacterial Resistance Leadership Group.
Satlin MJ, van Duin D, Tamma PD, Lodise TP, Van Tyne D, Rodvold KA, Rouphael N, Evans SR, Fowler VG, Hamasaki T, Patel R, Komarow L, Baum K, Souli M, Schwager N, Bonomo RA, Doi Y; Antibacterial Resistance Leadership Group. Satlin MJ, et al. Clin Infect Dis. 2023 Oct 16;77(Suppl 4):S305-S313. doi: 10.1093/cid/ciad547. Clin Infect Dis. 2023. PMID: 37843118
Priorities and Progress in Gram-positive Bacterial Infection Research by the Antibacterial Resistance Leadership Group: A Narrative Review.
Doernberg SB, Arias CA, Altman DR, Babiker A, Boucher HW, Creech CB, Cosgrove SE, Evans SR, Fowler VG, Fritz SA, Hamasaki T, Kelly BJ, Leal SM, Liu C, Lodise TP, Miller LG, Munita JM, Murray BE, Pettigrew MM, Ruffin F, Scheetz MH, Shopsin B, Tran TT, Turner NA, Williams DJ, Zaharoff S, Holland TL; Antibacterial Resistance Leadership Group. Doernberg SB, et al. Clin Infect Dis. 2023 Oct 16;77(Suppl 4):S295-S304. doi: 10.1093/cid/ciad565. Clin Infect Dis. 2023. PMID: 37843115 Review.
Global epidemiology and clinical outcomes of carbapenem-resistant Pseudomonas aeruginosa and associated carbapenemases (POP): a prospective cohort study.
Reyes J, Komarow L, Chen L, Ge L, Hanson BM, Cober E, Herc E, Alenazi T, Kaye KS, Garcia-Diaz J, Li L, Kanj SS, Liu Z, Oñate JM, Salata RA, Marimuthu K, Gao H, Zong Z, Valderrama-Beltrán SL, Yu Y, Tambyah P, Weston G, Salcedo S, Abbo LM, Xie Q, Ordoñez K, Wang M, Stryjewski ME, Munita JM, Paterson DL, Evans S, Hill C, Baum K, Bonomo RA, Kreiswirth BN, Villegas MV, Patel R, Arias CA, Chambers HF, Fowler VG Jr, Doi Y, van Duin D, Satlin MJ; Antibacterial Resistance Leadership Group and Multi-Drug Resistant Organism Network Investigators. Reyes J, et al. Lancet Microbe. 2023 Mar;4(3):e159-e170. doi: 10.1016/S2666-5247(22)00329-9. Epub 2023 Feb 9. Lancet Microbe. 2023. PMID: 36774938 Free PMC article.
Colistin Versus Ceftazidime-Avibactam in the Treatment of Infections Due to Carbapenem-Resistant Enterobacteriaceae.
van Duin D, Lok JJ, Earley M, Cober E, Richter SS, Perez F, Salata RA, Kalayjian RC, Watkins RR, Doi Y, Kaye KS, Fowler VG Jr, Paterson DL, Bonomo RA, Evans S; Antibacterial Resistance Leadership Group. van Duin D, et al. Clin Infect Dis. 2018 Jan 6;66(2):163-171. doi: 10.1093/cid/cix783. Clin Infect Dis. 2018. PMID: 29020404 Free PMC article.
64 results